The objective of study is to compare the anti-ischemic efficacy and safety profiles of once daily amlodipine or isosorbite-5-mononitrate in the treatment of stable asymptomatic and symptomatic myocardial ischemia

Condition	Intervention	Phase
Myocardial Ischemia	Drug: Amlodipine  Drug: iso- 5 - mononitrate  Procedure: Blood tests  Procedure: Exercise Stress Test	Phase IV

Further Study Details: 

Primary Outcomes: Evaluate the time to 1mm ST depression
Secondary Outcomes: The number of patients experiencing angina attacks The frequency of hospitalizations due to angina attacks Time to onset of 1mm ST segment depression Total external workload performed Safety
Expected Total Enrollment:  200

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Outpatients > =18 years of age with diagnosed clinically stable angina pectoris

Exclusion Criteria:

• Patients with congestive heart failure, clinically significant cardiovascular disease, standing systolic blood pressure of less than 100mmHg, concomitant anti-anginal therapies similar to sublingual NTG

Please refer to this study by ClinicalTrials.gov identifier  NCT00143195

Pfizer CT.gov Call Center      1-800-718-1021 

Greece
      Pfizer Investigational Site, Athens,  Greece; No longer recruiting
      Pfizer Investigational Site, Patra,  26335,  Greece; Recruiting
      Pfizer Investigational Site, THESSALONIKI,  54639,  Greece; Recruiting
      Pfizer Investigational Site, loannina,  45500,  Greece; Recruiting
      Pfizer Investigational Site, Voula/Athens,  Greece; Recruiting
      Pfizer Investigational Site, Holargos/Athens,  11525,  Greece; Recruiting
      Pfizer Investigational Site, THESSALONIKI,  546 36,  Greece; Recruiting
      Pfizer Investigational Site, Zakynthos,  29100,  Greece; Recruiting
Greece, Athens
      Pfizer Investigational Site, Agia Barbara,  Athens,  123 51,  Greece; Recruiting
Greece, Attika
      Pfizer Investigational Site, Athens,  Attika,  11527,  Greece; Recruiting

Study chairs or principal investigators

Pfizer CT.gov Call Center,  Study Director,  Pfizer   

Study ID Numbers:  A0531076
Last Updated:  September 1, 2005
Record first received:  August 31, 2005
ClinicalTrials.gov Identifier:  NCT00143195
Health Authority: Greece: National Organization of Medicines
ClinicalTrials.gov processed this record on 2005-09-06